Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03433183
Recruitment Status : Recruiting
First Posted : February 14, 2018
Last Update Posted : September 18, 2020
Sponsor:
Collaborators:
United States Department of Defense
AstraZeneca
Information provided by (Responsible Party):
Sarcoma Alliance for Research through Collaboration

Tracking Information
First Submitted Date  ICMJE January 29, 2018
First Posted Date  ICMJE February 14, 2018
Last Update Posted Date September 18, 2020
Actual Study Start Date  ICMJE October 2, 2019
Estimated Primary Completion Date September 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 23, 2018)
Clinical benefit rate of selumetinib in combination with sirolimus in patients with unresectable or metastatic NF1 associated or sporadic MPNST. [ Time Frame: Up to 6 months ]
An evaluable patient will be classified as a responder if the patient achieves a partial response (PR), complete response (CR) or stable disease (SD) ≥ 4 cycles.
Original Primary Outcome Measures  ICMJE
 (submitted: February 7, 2018)
Clinical benefit rate of selumetinib in combination with vistusertib in patients with unresectable or metastatic NF1 associated or sporadic MPNST. [ Time Frame: Up to 6 months ]
An evaluable patient will be classified as a responder if the patient achieves a partial response (PR), complete response (CR) or stable disease (SD) ≥ 4 cycles.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: July 23, 2018)
  • Progression free and overall survival [ Time Frame: Progression-Free Survival (PFS) is defined as the duration of time from the start of treatment to the time of objective progression or death. [Time Frame: Up to 4 years] ]
    Determined using the Kaplan-Meier method with PFS at important time points reported along with 95% two sided confidence intervals.
  • Define and describe the toxicities of selumetinib in combination with sirolimus in patients with unresectable or metastatic NF1 associated or sporadic MPNST. [ Time Frame: Up to 6 months ]
    This study will use CTEP Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for toxicity and adverse event reporting. The toxicities will be graded and summarized descriptively and tabulations on the type, severity and relationship to study treatment will be performed.
  • Assess the impact on pain interference [ Time Frame: Up to 6 months ]
    Pain interference metrics will be assessed using the Patient Reported Outcomes Measurements Information System (PROMIS) scale to assess the impact of pain on daily activities. This is a self-report measure that assesses the degree to which pain has interfered with the ability to complete daily activities over the past 7 days. Items are rated on a 5-point Likert scale and the measures yield standardized T-scores.
  • Assess the impact on pain severity [ Time Frame: Up to 6 months ]
    Pain metrics will be assessed using the Numerical Rating Scale-11 (NRS-11) scale to assess pain severity. The scale consists of a horizontal line with 0 representing "no pain" and 10 representing "worst pain you can imagine." Patients will circle one number from 0 to 10 that best describes how much their tumor pain hurt during the past week.
Original Secondary Outcome Measures  ICMJE
 (submitted: February 7, 2018)
  • Progression free and overall survival [ Time Frame: Progression-Free Survival (PFS) is defined as the duration of time from the start of treatment to the time of objective progression or death. [Time Frame: Up to 4 years] ]
    Determined using the Kaplan-Meier method with PFS at important time points reported along with 95% two sided confidence intervals.
  • Define and describe the toxicities of selumetinib in combination with vistusertib in patients with unresectable or metastatic NF1 associated or sporadic MPNST. [ Time Frame: Up to 6 months ]
    This study will use CTEP Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 for toxicity and adverse event reporting. The toxicities will be graded and summarized descriptively and tabulations on the type, severity and relationship to study treatment will be performed.
  • Assess the impact on pain interference [ Time Frame: Up to 6 months ]
    Pain interference metrics will be assessed using the PROMIS scale to assess the impact of pain on daily activities.
  • Assess the impact on pain severity [ Time Frame: Up to 6 months ]
    Pain metrics will be assessed using the NRS-11 scale to assess pain severity.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors
Official Title  ICMJE SARC031: A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination With the mTOR Inhibitor Sirolimus for Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors
Brief Summary To determine the clinical benefit rate of selumetinib in combination with sirolimus in patients with unresectable or metastatic neurofibromatosis type 1 (NF1) associated or sporadic MPNST.
Detailed Description

I. Primary Objective

• To determine the clinical benefit rate of selumetinib in combination with sirolimus in patients with unresectable or metastatic NF1 associated or sporadic MPNST

II. Secondary Objective(s)

  • To define and describe the toxicities of selumetinib in combination with sirolimus in patients with unresectable or metastatic NF1 associated or sporadic MPNST.
  • To assess the impact on intensity and pain interference and correlate to changes in clinical, imaging response and progression
  • To assess progression free and overall survival

Selumetinib will be given orally 50mg twice daily continuously and sirolimus will be given orally 4mg once daily with a cycle 1 day 1 loading dose of 12mg. One cycle will be 28 days. Patients will be able to remain on treatment as long as they do not experience progressive disease or unacceptable toxicity. Stage 1 will require 7 patients, with no further accrual if 0 of 7 respond. If 1 or greater of the 7 patients respond, accrual will continue until 21 patients have been enrolled.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description:
A Simon's two-stage phase 2 trial of MEK inhibitor selumetinib in combination with the mTOR inhibitor sirolimus to determine the safety and clinical benefit in patients with unresectable or metastatic MPNST
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Malignant Peripheral Nerve Sheath Tumors
  • Neurofibromatosis 1
Intervention  ICMJE
  • Drug: Selumetinib
    Selumetinib (AZD6244) is an oral selective inhibitor of the mitogen-activated protein kinase (MEK) 1/2 currently in development for adult malignancies, pediatric low-grade gliomas and NF1 plexiform neurofibromas. MEK is a critical kinase in the mitogen activated protein (MAP) kinase signal transduction pathway for many growth factor receptors that provide growth signals to cancer cells.
    Other Name: AZD6244
  • Drug: Sirolimus
    Sirolimus is a macrocyclic lactone produced by Streptomyces hygroscopicus and inhibitor of mammalian Target of Rapamycin (mTOR) serine threonine kinase, which plays a critical role in regulating cellular energy sensing, growth and metabolism.
    Other Name: Rapamycin
Study Arms  ICMJE Experimental: Selumetinib and Sirolimus
A Simon's two-stage phase 2 trial of MEK inhibitor selumetinib in combination with the mTOR inhibitor sirolimus to determine the safety and clinical benefit in patients with unresectable or metastatic MPNSTs. Both agents will be given orally on an empty stomach. Selumetinib will be given orally at a dose of 50mg twice daily continuously. Sirolimus will be given orally at a dose of 4mg once daily with a cycle 1 day 1 loading dose of 12mg. Each cycle will be considered 28 days.
Interventions:
  • Drug: Selumetinib
  • Drug: Sirolimus
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: February 7, 2018)
21
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE September 2021
Estimated Primary Completion Date September 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Age ≥ 12 years of age
  • Patients with unresectable or metastatic histologically confirmed sporadic or NF1 associated MPNST.
  • Patients must have measureable disease by RECIST.
  • Patients must have experienced progression after one or more prior regimens of cytotoxic chemotherapy. Patients who have refused cytotoxic chemotherapy or for whom treatment on this protocol prior to receiving cytotoxic chemotherapy is felt to be in the best interest for the patient by the local investigator will also be eligible.
  • Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering on this study.
  • No limitation on the number of prior chemotherapy regimens that the patient may have received prior to study entry.
  • The last dose of all myelosuppressive anticancer drugs must be at least 3 weeks prior to study entry.
  • The last dose of immunotherapy (monoclonal antibody or vaccine) must be at least 4 weeks prior to study entry.
  • The last dose of all biologic agents for the treatment of the patient's cancer (such as retinoids or tyrosine kinase inhibitors) must be at least 7 days prior to study entry.
  • The last dose of radiation to more than 25% of marrow containing bones (pelvis, spine, skull) must be at least 4 weeks prior to study entry. The last dose of all other local palliative (limited port) radiation must be at least 2 weeks prior to study entry.
  • At least 2 months post-autologous stem cell transplant or at least 3 months post-allogeneic transplant and recovered from toxicities without evidence of graft versus host disease and on stable doses of immunosuppressive medications if required.
  • The last dose of colony stimulating factors, such as filgrastim, sargramostim, and erythropoietin, must be at least 1 week prior to study entry, the last dose of long-acting colony stimulating factors, such as pegfilgrastim, must be at least 2 weeks prior to study entry.
  • No other anti-cancer therapy (chemotherapy, biological therapy, radiation therapy) is permitted.
  • Karnofsky performance level ≥ 50%.
  • Patients who are unable to walk because of paralysis or motor weakness, but who are up in a wheelchair will be considered ambulatory for the purpose of calculating the performance score.
  • Peripheral absolute neutrophil count (ANC) of ≥1000/μL
  • Platelet count ≥75,000/μL (transfusion independent (no transfusion within at least 7 days prior to enrollment)
  • Total bilirubin must be ≤ 1.5 times the upper limit of normal (ULN)
  • SGPT (ALT) must be ≤ 3.0 times ULN
  • Serum creatinine ≤ ULN or creatinine clearance >60 ml/min/1.73 m2
  • Serum triglyceride level ≤300 mg/dL and serum cholesterol level ≤ 300 mg/dL (Patient may be on lipid-lowering medicine)
  • Normal ejection fraction by ECHO or cardiac MRI >55%
  • QTcF ≤ 450ms
  • Fertile men and women of childbearing potential must agree to use an effective method of birth control.
  • Patients with central nervous system disease are eligible for enrollment if they have received prior radiotherapy or surgery to sites of CNS metastatic disease and are without evidence of clinical progression or stable disease at 4 weeks.

Exclusion Criteria:

  • Patients receiving other anti-cancer agents are not eligible.
  • Patients who cannot swallow whole pills.
  • Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent (for example cyclosporine). Topical or inhaled corticosteroids are allowed.
  • Patients should not receive immunizations with attenuated live vaccines within four weeks of study entry or during study period.
  • Any recent major surgery within a minimum of 4 weeks, with the exception of surgical placement for vascular access, or minor surgery (excluding tumor biopsies) within 14 days.
  • Patients who any known severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as:

    • Severely impaired lung function defined as spirometry and DLCO that is 50% of the normal predicted value corrected for hemoglobin and alveolar volume and/or O2 saturation that is 88% or less at rest on room air. For patients who do NOT have respiratory symptoms (e.g. dyspnea at rest, known requirement for supplemental oxygen), pulmonary function test is not required.
    • Cardiac conditions as follows:

      • Uncontrolled hypertension (blood pressure ≥150/95 mmHg despite medical therapy).
      • Acute coronary syndrome within 6 months prior to starting treatment
      • Uncontrolled angina despite medical therapy
      • Symptomatic heart failure NYHA Class II-IV prior or current cardiomyopathy, or severe valvular disease
      • Prior or current cardiomyopathy
    • Uncontrolled Type 1 or 2 diabetes as defined by fasting serum glucose >1.5 x ULN
    • Uncontrolled infection
    • Pre-existing renal disease including glomerulonephritis, nephritic syndrome, Fanconi Syndrome, or renal tubular acidosis.
    • Current refractory nausea and vomiting, malabsorption syndrome, disease significantly affecting gastrointestinal function, resection of small bowel, symptomatic inflammatory bowel disease, or ulcerative colitis, or partial or complete bowel obstruction.
    • Ophthalmological conditions as follows:

      • Current or past history of retinal pigment epithelial detachment (RPED)/central serous retinopathy (CSR) or retinal vein occlusion
      • Intraocular pressure (IOP) > 21 mmHg or uncontrolled glaucoma
  • Supplementation with vitamin E greater than 100% of the daily recommended dose.
  • Hypersensitivity to active or inactive excipients of rapamycins (sirolimus, temsirolimus or everolimus) or selumetinib or drugs with similar chemical structures or class to sirolimus or selumetinib.
  • Patients unwilling or unable to comply with the protocol.
  • Seville orange, star fruit, grapefruit and their juices, and St. John's Wort use are not allowed while on study.
  • Exposure to strong or moderate inhibitors or inducers of CYP3A4/5, Pgp (MDR1) and BCRP if taken within the stated washout periods before the first dose of study treatment.
  • Exposure to specific substrates of drug transporters OATP1B1, OATP1B3, MATE1 and MATE2K within the appropriate washout periods (a minimum of 5 x reported elimination half-life) before the first dose of study treatment.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 12 Years and older   (Child, Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: SARC Office (734) 930-7600 sarc@sarctrials.org
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03433183
Other Study ID Numbers  ICMJE SARC031
CDMRP-NF150092 ( Other Grant/Funding Number: Department of Defense )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Sarcoma Alliance for Research through Collaboration
Study Sponsor  ICMJE Sarcoma Alliance for Research through Collaboration
Collaborators  ICMJE
  • United States Department of Defense
  • AstraZeneca
Investigators  ICMJE
Principal Investigator: AeRang Kim, MD, PhD Children's National Research Institute
Principal Investigator: Brigitte Widemann, MD National Cancer Institute (NCI)
PRS Account Sarcoma Alliance for Research through Collaboration
Verification Date September 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP